Cargando…
Leveraging the utility of pharmacogenomics in psychiatry through clinical decision support: a focus group study
BACKGROUND: Pharmacogenomics is starting to build momentum in clinical utility, perhaps the most in mental and behavioral healthcare. However, efficient delivery of this information to the point of prescribing remains a significant challenge. Clinical decision support has an opportunity to address t...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6688280/ https://www.ncbi.nlm.nih.gov/pubmed/31413721 http://dx.doi.org/10.1186/s12991-019-0237-3 |
_version_ | 1783442854870253568 |
---|---|
author | Goodspeed, Andrew Kostman, Nicolas Kriete, Trenton E. Longtine, Joel W. Smith, Sean M. Marshall, Peregrin Williams, Wesley Clark, Cheryl Blakeslee, Weston W. |
author_facet | Goodspeed, Andrew Kostman, Nicolas Kriete, Trenton E. Longtine, Joel W. Smith, Sean M. Marshall, Peregrin Williams, Wesley Clark, Cheryl Blakeslee, Weston W. |
author_sort | Goodspeed, Andrew |
collection | PubMed |
description | BACKGROUND: Pharmacogenomics is starting to build momentum in clinical utility, perhaps the most in mental and behavioral healthcare. However, efficient delivery of this information to the point of prescribing remains a significant challenge. Clinical decision support has an opportunity to address this void by integrating pharmacogenomics into the clinician workflow. METHODS: To address the specific needs of mental health clinicians at the point of care, we conducted 3 focus groups with a total of 16 mental health clinicians. Each 1-h focus group was designed to identify the desired clinical decision support features, with a particular interest in pharmacogenomics, and potential negative or unintended consequences of clinical decision support integration at the point of care in a mental healthcare setting. We implemented an iterative design to expand upon knowledge generated in prior focus groups. The results from the guided discussion in the first focus group were used to develop a mental health clinical decision support prototype. This prototype was then presented during the next two focus groups to drive the discussion. RESULTS: This study has identified main themes related to the desired clinical decision support features of mental health clinicians, the use of pharmacogenomics in practice, and unintended and negative consequences of clinical decision support integration at the point of care. Clinicians desire a more complete picture of the medication history of patients and guidance to choose medications in relation to cost, insurance coverage, and pharmacogenetics interactions. Mental health clinicians agreed that pharmacogenetics is useful and impacts their prescribing decisions when the data are available. Several negative consequences of clinical decision support integration were identified including alert fatigue and frustration using the tool. Several points of contention were related to the integration of the clinical decision support with the electronic health record, including bidirectional flow of information, speed, location within workflow, and potential incompleteness of information. CONCLUSIONS: We have identified general and unique considerations of mental health clinicians with regard to clinical decision support. Clinical decision support that incorporates desired features while avoiding negative and unintended consequences will increase clinician usage and will have the potential to improve the care of patients. |
format | Online Article Text |
id | pubmed-6688280 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-66882802019-08-14 Leveraging the utility of pharmacogenomics in psychiatry through clinical decision support: a focus group study Goodspeed, Andrew Kostman, Nicolas Kriete, Trenton E. Longtine, Joel W. Smith, Sean M. Marshall, Peregrin Williams, Wesley Clark, Cheryl Blakeslee, Weston W. Ann Gen Psychiatry Primary Research BACKGROUND: Pharmacogenomics is starting to build momentum in clinical utility, perhaps the most in mental and behavioral healthcare. However, efficient delivery of this information to the point of prescribing remains a significant challenge. Clinical decision support has an opportunity to address this void by integrating pharmacogenomics into the clinician workflow. METHODS: To address the specific needs of mental health clinicians at the point of care, we conducted 3 focus groups with a total of 16 mental health clinicians. Each 1-h focus group was designed to identify the desired clinical decision support features, with a particular interest in pharmacogenomics, and potential negative or unintended consequences of clinical decision support integration at the point of care in a mental healthcare setting. We implemented an iterative design to expand upon knowledge generated in prior focus groups. The results from the guided discussion in the first focus group were used to develop a mental health clinical decision support prototype. This prototype was then presented during the next two focus groups to drive the discussion. RESULTS: This study has identified main themes related to the desired clinical decision support features of mental health clinicians, the use of pharmacogenomics in practice, and unintended and negative consequences of clinical decision support integration at the point of care. Clinicians desire a more complete picture of the medication history of patients and guidance to choose medications in relation to cost, insurance coverage, and pharmacogenetics interactions. Mental health clinicians agreed that pharmacogenetics is useful and impacts their prescribing decisions when the data are available. Several negative consequences of clinical decision support integration were identified including alert fatigue and frustration using the tool. Several points of contention were related to the integration of the clinical decision support with the electronic health record, including bidirectional flow of information, speed, location within workflow, and potential incompleteness of information. CONCLUSIONS: We have identified general and unique considerations of mental health clinicians with regard to clinical decision support. Clinical decision support that incorporates desired features while avoiding negative and unintended consequences will increase clinician usage and will have the potential to improve the care of patients. BioMed Central 2019-08-08 /pmc/articles/PMC6688280/ /pubmed/31413721 http://dx.doi.org/10.1186/s12991-019-0237-3 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Primary Research Goodspeed, Andrew Kostman, Nicolas Kriete, Trenton E. Longtine, Joel W. Smith, Sean M. Marshall, Peregrin Williams, Wesley Clark, Cheryl Blakeslee, Weston W. Leveraging the utility of pharmacogenomics in psychiatry through clinical decision support: a focus group study |
title | Leveraging the utility of pharmacogenomics in psychiatry through clinical decision support: a focus group study |
title_full | Leveraging the utility of pharmacogenomics in psychiatry through clinical decision support: a focus group study |
title_fullStr | Leveraging the utility of pharmacogenomics in psychiatry through clinical decision support: a focus group study |
title_full_unstemmed | Leveraging the utility of pharmacogenomics in psychiatry through clinical decision support: a focus group study |
title_short | Leveraging the utility of pharmacogenomics in psychiatry through clinical decision support: a focus group study |
title_sort | leveraging the utility of pharmacogenomics in psychiatry through clinical decision support: a focus group study |
topic | Primary Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6688280/ https://www.ncbi.nlm.nih.gov/pubmed/31413721 http://dx.doi.org/10.1186/s12991-019-0237-3 |
work_keys_str_mv | AT goodspeedandrew leveragingtheutilityofpharmacogenomicsinpsychiatrythroughclinicaldecisionsupportafocusgroupstudy AT kostmannicolas leveragingtheutilityofpharmacogenomicsinpsychiatrythroughclinicaldecisionsupportafocusgroupstudy AT krietetrentone leveragingtheutilityofpharmacogenomicsinpsychiatrythroughclinicaldecisionsupportafocusgroupstudy AT longtinejoelw leveragingtheutilityofpharmacogenomicsinpsychiatrythroughclinicaldecisionsupportafocusgroupstudy AT smithseanm leveragingtheutilityofpharmacogenomicsinpsychiatrythroughclinicaldecisionsupportafocusgroupstudy AT marshallperegrin leveragingtheutilityofpharmacogenomicsinpsychiatrythroughclinicaldecisionsupportafocusgroupstudy AT williamswesley leveragingtheutilityofpharmacogenomicsinpsychiatrythroughclinicaldecisionsupportafocusgroupstudy AT clarkcheryl leveragingtheutilityofpharmacogenomicsinpsychiatrythroughclinicaldecisionsupportafocusgroupstudy AT blakesleewestonw leveragingtheutilityofpharmacogenomicsinpsychiatrythroughclinicaldecisionsupportafocusgroupstudy |